Premium
Role of different normal hematopoietic regulatory proteins in the differentiation of myeloid leukemic cells
Author(s) -
Lotem Joseph,
Shabo Yosef,
Sachs Leo
Publication year - 1988
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910410119
Subject(s) - haematopoiesis , myeloid , biology , clone (java method) , interleukin 3 , immunology , microbiology and biotechnology , gene , genetics , stem cell , t cell , interleukin 21 , immune system
There are 4 different normal myeloid hematopoietic cell growth‐inducing proteins MGI‐I (CSF or IL‐3) that induce normal precursor cells to multiply and form clones containing only macrophages (MGI‐IM = M‐CSF = CSF‐I), only granu‐locytes (MGI‐IG = G‐CSF), both granulocytes and macrophages (MGI‐IGM = GM‐CSF), or granulocytes, macrophages, eosinophils, mast cells, megakaryocytes and erythroid cells (interleukin‐3) (IL‐3). There is another type of normal myeloid regulatory protein (MGI‐2) with no MGI‐I (CSF or IL‐3) activity which can induce differentiation of normal myeloid precursors and certain clones of myeloid leukemic cells. The present results with MGI‐2 and pure recombinant MGI‐IG, MGI‐IGM and IL‐3 have shown that different clones of myeloid leukemic cells can be induced to differentiate by different hematopoietic regulatory proteins. One type of leukemic clone is induced to differentiate to mature cells only by MGI‐2 and is partially differentiated by MGI‐IG, a second type is differentiated only by MGI‐IGM or IL‐3, and other workers have found a third type that is differentiated only by MGI‐IG. The presence of surface receptors does nat necessarily make leukemic cells differentiation competent for these hematopoietic regulatory proteins. All 4 types of MGI‐I (CSF or IL‐3) induce endogenous synthesis of MGI‐2 in normal myeloid precursor ceils. It is suggested that, in addition to their potential therapeutic effect on the development of normal hematopoietic cells, MGI‐2, MGI‐IG, MGI‐IGM and IL‐3 all have the potential for differentiation‐directed therapy of leukemia in leukemic cells that can be differentiated by one of these normal hematopoietic regulatory proteins.